A translational research study performed with samples obtained from a cohort of patients with triple-negative breast cancer (TNBC) enrolled in the neoadjuvant GeparQuinto (GBG 44) study has been published in the Journal of Clinical Oncology.
BRCA1/2 mutations are frequent in patients with TNBC. Therefore, the efficacy of a given treatment regimen may depend on BRCA mutation status. In this study the addition of bevacizumab has been shown to increase the pathological complete response (pCR) after standard neoadjuvant treatment for patients with BRCA1/2 mutations. However, the pCR was a strong predictor of survival (disease-free survival) only for patients without BRCA1/2 mutations treated with anthracycline and taxane-based chemotherapy (with or without bevacizumab).
Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol. 2018; 36:2281-2287